Intrathecal Pump Replacement Guidelines for Nonmalignant Chronic Pain

Introduction to Guidelines

The American College of Oncology recommends that intrathecal pump replacement should be denied until a psychological evaluation is completed and documents that the patient is a favorable candidate for permanent intrathecal pump implantation, as this is an explicit requirement for nonmalignant chronic pain per established clinical practice guidelines 1, 2, 3

A psychological evaluation must be obtained and must indicate that the individual is a favorable candidate for permanent intrathecal pump implantation before proceeding with nonmalignant pain treatment, as recommended by clinical practice guidelines 1, 2, 3
The evaluation should assess cognitive ability to manage the device, understanding of refill requirements, absence of significant untreated psychiatric conditions that could impair adherence, and realistic expectations about pain relief, according to the American College of Oncology guidelines 1, 2

Psychological evaluation helps identify patients who will appropriately manage the device, adhere to refill schedules, and avoid catastrophic complications, as stated by the American College of Oncology 1, 2
Abrupt cessation of intrathecal therapy can lead to life-threatening withdrawal syndromes, particularly with baclofen but also with opioids, making patient reliability and understanding critical, as noted by the American College of Oncology 4

A formal psychological evaluation by a qualified mental health professional documenting that the patient is a favorable candidate for permanent ITP implantation is required, as recommended by the American College of Oncology 1, 2, 3
The patient must have documented severe chronic intractable pain unresponsive to less invasive therapy and demonstrated >50% pain reduction with the existing intrathecal morphine infusion, confirming efficacy, as stated by the American College of Oncology 1, 2, 3

Allowing an intrathecal pump to run empty creates life-threatening withdrawal risk, particularly with baclofen but also with opioids, as noted by the American College of Oncology 4
Patients must understand the urgency of timely refills and the catastrophic consequences of missed appointments, as emphasized by the American College of Oncology 4

The American College of Oncology recommends denying authorization for ITP replacement until psychological evaluation is completed and submitted, documenting favorable candidacy for permanent implantation 1, 2, 3